Juvenescence is creating antiaging therapies using artificial intelligence and biotechnology with a near term goal of extending human lifespan to 150 years. They just raised $100 million in a Series B round, including a total of $10 million from its founders and a further $10 million each from four cornerstone investors, including Grok Ventures, the investment company of Mike Cannon-Brookes (Atlassian cofounder), and Michael Spencer’s private investment company, IPGL.
This brings the total to $165 Million that Juvenescence has raised in 18 months and speaks to the extraordinary opportunity as well as interest in developing therapeutics with the capacity to modify aging.
They have 12 programs based on hard, rigorous science, to attempt to modify aging. They range from stem cell research to senolytics (removing zombie cells) to modifying or preventing Alzheimer’s and Parkinson’s diseases.
The Juvenescence teams believes within five to seven years at least four anti-aging products will be on the market from their portfoilo of about one dozen antiaging companies.